Furthermore, in a bleomycin‐induced mouse model of pulmonary fibrosis, treatment with PBI‐4050, described as a GPR84 modulator and GPR40 agonist, caused a 47% reduction of histological lesions in the lung (compared with vehicle),1 supporting a role for GPR84 in fibrotic disease. This evidence concerns the gene FFAR1 and pulmonary fibrosis.